Edition:
United Kingdom

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

4.60USD
14 Dec 2018
Change (% chg)

$-0.09 (-1.92%)
Prev Close
$4.69
Open
$4.66
Day's High
$4.70
Day's Low
$4.56
Volume
249,983
Avg. Vol
460,569
52-wk High
$9.41
52-wk Low
$4.24

Latest Key Developments (Source: Significant Developments)

Progenics Pharmaceuticals Q3 Loss Per Share $0.30
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.Q3 LOSS PER SHARE $0.30.Q3 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.QUARTERLY TOTAL REVENUES $5.3 MILLION VERSUS $2.7 MILLION.  Full Article

Progenics Reports Results of Phase 2/3 Trial of Imaging Agent for Detection of Prostate Cancer
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS - DIAGNOSTIC PERFORMANCE OF PYL MET FIRST CO-PRIMARY ENDPOINT OF PHASE 2/3 TRIAL .PROGENICS REPORTS RESULTS OF PHASE 2/3 TRIAL OF PSMA PET IMAGING AGENT PYL FOR THE DETECTION OF PROSTATE CANCER.PROGENICS PHARMACEUTICALS - RESULTS OF PHASE 3 TRIAL OF PSMA PET IMAGING AGENT PYL FOR DETECTION OF PROSTATE CANCER TO COMMENCE BY YEAR END.PROGENICS PHARMACEUTICALS INC - 27 SUBJECTS EXPERIENCED AT LEAST ONE TREATMENT RELATED ADVERSE EVENT.PROGENICS PHARMACEUTICALS INC - 18F‐DCFPYL WAS VERY WELL TOLERATED IN PHASE 2/3 TRIAL.PROGENICS PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS RELATED TO STUDY DRUG.PROGENICS PHARMACEUTICALS INC - PHASE 3 TRIAL OF PSMA PET IMAGING AGENT PYL TO COMMENCE BY YEAR END.  Full Article

Progenics Pharmaceuticals Reports Top Line Phase 3 Data For Prostate Cancer Imaging Agent 1404
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS REPORTS TOP LINE PHASE 3 DATA FOR PROSTATE CANCER IMAGING AGENT 1404.PROGENICS PHARMA - 1404 MEETS CO-PRIMARY ENDPOINT OF SPECIFICITY; 1404 SUCCESSFULLY IDENTIFIES PATIENTS WITHOUT CLINICALLY SIGNIFICANT PROSTATE CANCER.PROGENICS PHARMACEUTICALS - ANTICIPATE FINALIZING CLINICAL DEVELOPMENT PLAN WITH FDA FOR 1095 IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN Q4.PROGENICS PHARMACEUTICALS - CO-PRIMARY ENDPOINT OF SENSITIVITY TO IDENTIFY PATIENTS WITH CLINICALLY SIGNIFICANT DISEASE NOT MET IN PHASE 3 STUDY FOR 1404.PROGENICS PHARMACEUTICALS - EXPECT PARTNER BAYER TO INITIATE PHASE 1 STUDY OF PSMA-TTC IN PATIENTS WITH MCRPC BY YEAR END 2018.  Full Article

Progenics Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO USE NET PROCEEDS FROM OFFERING FOR RESEARCH AND DEVELOPMENT.  Full Article

FDA Approves First Treatment For Rare Adrenal Tumors
Monday, 30 Jul 2018 

July 30 (Reuters) - U.S. Food and Drug Administration: :FDA APPROVES FIRST TREATMENT FOR RARE ADRENAL TUMORS.U.S. FDA SAYS APPROVED AZEDRA INJECTION FOR INTRAVENOUS USE FOR TREATMENT OF ADULTS, ADOLESCENTS AGE 12 AND OLDER WITH RARE TUMORS OF ADRENAL GLAND.FDA SAYS GRANTED APPROVAL OF AZEDRA TO PROGENICS PHARMACEUTICALS, INC.  Full Article

Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating To Patent Infringement
Friday, 11 May 2018 

May 11 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMA-ON MAY 10, CO, VALEANT, AMONG OTHERS & PAR STERILE PRODUCTS, PAR PHARMA ENTERED SETTLEMENT AGREEMENT RELATING TO PATENT INFRINGEMENT.PROGENICS PHARMA- CO,OTHER PLAINTIFFS ALLEGE PRODUCTS FOR WHICH PAR IS SEEKING U.S. MARKETING APPROVAL INFRINGES CO'S,OTHER PLAINTIFFS' U.S. PATENTS.  Full Article

Progenics Pharmaceuticals Announces FDA Acceptance Of Marketing Application For Azedra In Pheochromocytoma And Paraganglioma
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AZEDRA® (IOBENGUANE I 131) IN PHEOCHROMOCYTOMA AND PARAGANGLIOMA.PROGENICS PHARMACEUTICALS - ‍FDA GRANTED CO REQUEST FOR PRIORITY REVIEW; HAS SET ACTION DATE OF APRIL 30, 2018 UNDER PDUFA​.  Full Article

Progenics Pharmaceuticals Q3 loss per share $0.22
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals announces third quarter 2017 financial results and business update.Q3 loss per share $0.22.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.Progenics Pharmaceuticals Inc - ‍Q3 revenue totaled $2.7 million, down from $53.9 million in Q3 of 2016​.Progenics - ‍ended Q3 with cash and cash equivalents of $98.3 million, decrease of $40.6 million versus cash and cash equivalents as of December 31, 2016​.  Full Article

Progenics Pharmaceuticals announces positive topline results from registrational Phase 2B trial of Azedra®
Thursday, 30 Mar 2017 

Progenics Pharmaceuticals Inc : Progenics Pharmaceuticals announces positive topline results from registrational phase 2b trial of azedra® . Progenics Pharmaceuticals Inc - study achieves primary endpoint . Progenics Pharmaceuticals Inc - secondary endpoint shows favorable tumor response to therapy .Progenics Pharmaceuticals Inc - company to submit nda in mid-2017.  Full Article

UPDATE 1-FDA approves Progenics' treatment for rare adrenal gland tumors

July 30 The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use.